Status:
RECRUITING
Validation of the TheraSure CNI-Monitor Under Immuno-checkpoint-therapy (Hereinafter: "Immunotherapy") in NSCLC in Palliative Therapy
Lead Sponsor:
Karsten Gavenis
Collaborating Sponsors:
Chronix Biomedical Corporation
Conditions:
NSCLC
Eligibility:
All Genders
18+ years
Brief Summary
This is a prospective, non-interventional, national study planned at three centers for patients with non-curative NSCLC receiving immunotherapy. At present, PD-L1 expression or tumor mutation burden ...
Eligibility Criteria
Inclusion
- Signed informed consent form
- Age ≥18 years
- NSCLC, non-curatively treatable stage III or stage IV with palliative treatment indication
- Immunocheckpoint-therapy for malignant disease (Immunotherapy as monotherapy, double immunotherapy or combination with chemotherapy)
Exclusion
- Person is unable to understand the nature, importance and scope of the clinical trial
- Participation in an interventional study
- Hb value \<9g/dl
Key Trial Info
Start Date :
February 24 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2028
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT05426668
Start Date
February 24 2025
End Date
February 1 2028
Last Update
January 5 2026
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Göttingen
Göttingen, Lower Saxony, Germany, 37075
2
Medizinische Hochschule Hannover
Hanover, Germany, 30625
3
Pius-Hospital Oldenburg
Oldenburg, Germany, 26121